Cdk5 is a key factor in tau aggregation and tangle formation in vivo

Neuron

Volumn 38, Issue 4, 2003, Pages 555-565

  Noble, Wendy ^a   Olm, Vicki ^a   Takata, Kazuyuki ^a   Casey, Evelyn ^a   Mary, O ^a   Meyerson, Jordana ^a   Gaynor, Kate ^a   LaFrancois, John ^a   Wang, Lili ^a   Kondo, Takayuki ^a   Davies, Peter ^b   Burns, Mark ^a   Veeranna, ^a   Nixon, Ralph ^a   Dickson, Dennis ^c   Matsuoka, Yasuji ^a   Ahlijanian, Michael ^d   Lau, Lit Fui ^d   Duff, Karen ^a  

^a NEW YORK UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; MUTANT PROTEIN; PROTEIN; PROTEIN P25; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN STEM; CONTROLLED STUDY; GENE OVEREXPRESSION; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

EID: 0038689162     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00259-9     Document Type: Article

References (49)

1. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E.et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. USA. 97:2000;2910-2915.
2. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA. 98:2001;6923-6928.
3. Alvarez A., Munoz J.P., Maccioni R.B. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp. Cell Res. 264:2001;266-274.
4. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.). 103:2002;26-35.
5. Bancroft J.D., Stevens A. Theory and Practice of Histological Techniques. Third Edition:1990;Churchill Livingstone, Edinburgh.
6. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336:1993;417-424.
7. Bian F., Nath R., Sobocinski G., Booher R.N., Lipinski W.J., Callahan M.J., Pack A., Wang K.K., Walker L.C. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol. 446:2002;257-266.
8. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules. distinction between PHF-like immunoreactivity and microtubule binding Neuron. 11:1993;153-163.
9. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein. effects on microtubule interaction, intracellular trafficking and neurodegeneration Biochem. J. 323:1997;577-591.
10. Braak H., Braak E., Ohm T., Bohl J. Silver impregnation of Alzheimer's neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 63:1988;197-200.
11. Bu B., Li J., Davies P., Vincent I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22:2002;6515-6525.
12. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M.et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7:2000;87-98.
13. Flaherty D.B., Soria J.P., Tomasiewicz H.G., Wood J.G. Phosphorylation of human tau protein by microtubule-associated kinases. GSK3beta and cdk5 are key participants J. Neurosci. Res. 62:2000;463-472.
14. Friedhoff P., von Bergen M., Mandelkow E.M., Mandelkow E. Structure of tau protein and assembly into paired helical filaments. Biochim. Biophys. Acta. 1502:2000;122-132.
15. Gotz J., Nitsch R.M. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. Neuroreport. 12:2001;2007-2016.
16. Gotz J., Chen F., Van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 293:2001;1491-1495.
17. Greenberg S.G., Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA. 87:1990;5827-5831.
18. Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.C., Zaidi M.S., Wisniewski H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261:1986;6084-6089.
19. Grynspan F., Griffin W.R., Cataldo A., Katayama S., Nixon R.A. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. 763:1997;145-158.
20. Hashiguchi M., Saito T., Hisanaga S.I., Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277:2002;44525-44530.
21. Ishiguro K., Sato K., Takamatsu M., Park J., Uchida T., Imahori K. Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci. Lett. 202:1995;81-84.
22. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 34:2002;509-519.
23. Lee K.Y., Clark A.W., Rosales J.L., Chapman K., Fung T., Johnston R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34:1999;21-29.
24. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
25. Lew J., Huang Q.Q., Qi Z., Winkfein R.J., Aebersold R., Hunt T., Wang J.H. A brain-specific activator of cyclin-dependent kinase 5. Nature. 371:1994;423-426.
26. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul M.M., Baker M., Yu X.et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:2000;402-405.
27. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D.et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491.
28. Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett. 530:2002;209-214.
29. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
30. Lund E.T., McKenna R., Evans D.B., Sharma S.K., Mathews W.R. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J. Neurochem. 76:2001;1221-1232.
31. Michel G., Mercken M., Murayama M., Noguchi K., Ishiguro K., Imahori K., Takashima A. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p25) transfected cells. Biochim. Biophys. Acta. 1380:1998;177-182.
32. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
33. Paudel H.K., Lew J., Ali Z., Wang J.H. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268:1993;23512-23518.
34. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56:1997;70-78.
35. Planel E., Sun X., Takashima A. Role of GSK-3β in Alzheimer's disease pathology. Drug Dev. Res. 56:2002;491-510.
36. Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B., Fleck T.J., Johnston J.A., Sharma S.K. Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 514:2002;263-268.
37. Ratner N., Bloom G.S., Brady S.T. A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport. effects defined by olomoucine and the APC tumor suppressor protein J. Neurosci. 18:1998;7717-7726.
38. Sengupta A., Wu Q.L., Grundke-Iqbal I., Iqbal K., Singh T.J. Potentiation of GSK-3 catalysed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167:1997;99-105.
39. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357:1998;299-309.
40. Spittaels K., Van den H.C., Van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T.et al. Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275:2000;41340-41349.
41. Takashima A., Noguchi K., Sato K., Hoshino T., Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 90:1993;7789-7793.
42. Tomidokoro Y., Ishiguro K., Harigaya Y., Matsubara E., Ikeda M., Park J.M., Yasutake K., Kawarabayashi T., Okamoto K., Shoji M. Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci. Lett. 299:2001;169-172.
43. Town T., Zolton J., Shaffner R., Schnell B., Crescentini R., Wu Y., Zeng J., DelleDonne A., Obregon D., Tan J.et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69:2002;362-372.
44. Tseng H.C., Zhou Y., Shen Y., Tsai L.H. A survey of cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523:2002;58-62.
45. Tsuji T., Shimohama S., Kinura J., Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci. Lett. 248:1998;109-112.
46. Veeranna, Shetty K.T., Amin N., Grant P., Albers R.W., Pant H.C. Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18. Neurochem. Res. 21:1996;629-636.
47. Veeranna, Amin N.D., Ahn N.G., Jaffe H., Winters C.A., Grant P., Pant H.C. Mitogen-activated protein kinases (ERK1,2) phosphorylate Lys-Ser-Pre (KSP) repeats in neurofilament proteins NF-H and NF-M. J. Neurosci. 18:1998;4008-4021.
48. Williamson R., Scales T., Clark B.R., Gibb G., Reynolds C.H., Kellie S., Bird I.N., Varndell I.M., Sheppard P.W., Everall I.et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure. involvement of Src family protein kinases J. Neurosci. 22:2002;10-20.
49. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl.). 92:1996;232-241.